FIELD: medicine; oncology.
SUBSTANCE: invention can be used to determine the risk of malignant transformation of epithelial cells of the larynx in patients with precancerous diseases of the larynx. A patient tissue sample is obtained by taking a biopsy of the larynx. The laryngeal epithelium is examined, the expression level of the PSMB5 gene in it is assessed in relation to the expression of the reference GAPDH gene using RT-qPCR. In clarified homogenates, the chymotrypsin-like activity of proteasomes (CTP) and the activity of calpains are determined. The value of the probability of malignant transformation is calculated by the formula P=1/(1+e-F). With a value of R≥0.5 a high risk of malignant transformation of epithelial cells of the larynx in patients with precancerous diseases of the larynx is predicted.
EFFECT: method provides increased accuracy and information value of determining the risk of malignant transformation of laryngeal epithelial cells due to the use of new markers: PSMB5 expression, CTP proteasome activity and calpain activity.
1 cl, 3 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF RISK OF DEVELOPING DISTANT METASTASES IN PATIENTS WITH OPERABLE FORMS OF BREAST CANCER WITH METASTASES IN REGIONAL LYMPH NODES | 2020 |
|
RU2733697C1 |
| METHOD FOR DISTANT METASTASES DEVELOPMENT RISK DEGREE DETERMINATION FOR PATIENTS WITH COLON CANCER | 2016 |
|
RU2623119C1 |
| METHOD FOR EVALUATING THE DEGREE OF RISK OF ADVERSE EVALUATION OF DISEASE IN PATIENTS WITH GASTRIC CANCER | 2016 |
|
RU2662085C1 |
| METHOD FOR PREDICTING AN UNFAVORABLE OUTCOME IN NON-SMALL-CELL LUNG CANCER | 2019 |
|
RU2696872C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF LEUKOPLAKIA AND SQUAMOUS CELL CARCINOMA OF THE ORAL MUCOSA AT THE PREOPERATIVE STAGE | 2021 |
|
RU2770354C1 |
| METHOD FOR ASSESSING ENDOMETRIAL CANCER PROGRESSION IN PATIENTS WITH HYPERPLASTIC PROCESSES IN ENDOMETRIUM | 2014 |
|
RU2554505C1 |
| METHOD FOR PREDICTION OF CLINICAL OUTCOME OF MUSCULO-INVASIVE BLADDER CANCER FOLLOWING COMBINATION THERAPY | 2012 |
|
RU2538632C2 |
| METHOD FOR PREDICTING THE OUTCOME OF A DISEASE IN PATIENTS WITH LUMINAL AND THRICE NEGATIVE BREAST CANCER IN PATIENTS WHO DID NOT RECEIVE CHEMOTHERAPY OR HORMONE THERAPY IN THE NEOADJUVANT REGIMEN | 2017 |
|
RU2648523C1 |
| METHOD FOR PREDICTION OF DEVELOPING HAEMATOGENOUS METASTASES FOLLOWING COMBINED TREATMENT OF KIDNEY CANCER | 2013 |
|
RU2528100C1 |
| METHOD FOR PREDICTION OF RISK OF HEMATOGENOUS METASTASES IN NON-SMALL-CELL LUNG CANCER PATIENTS AFTER OPERATION | 2019 |
|
RU2733160C1 |
